BIOMARIN PHARMACEUTICAL INC

Form 4

January 08, 2014

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF

SECURITIES

OMB Number:

3235-0287

Expires:

5. Relationship of Reporting Person(s) to

(Check all applicable)

10% Owner

Issuer

X Director

January 31, 2005

0.5

Estimated average

response...

burden hours per

OMB APPROVAL

subject to Section 16. Form 4 or Form 5

Check this box

if no longer

obligations

may continue.

See Instruction

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section

30(h) of the Investment Company Act of 1940

2. Issuer Name and Ticker or Trading

BIOMARIN PHARMACEUTICAL

Symbol

(Middle)

INC [BMRN]

3. Date of Earliest Transaction

1(b).

(Last)

(Print or Type Responses)

1. Name and Address of Reporting Person *

(First)

BIENAIME JEAN JACQUES

C/O BION PHARMA DIGITAL	CEUTICAL INC	01/06/	/Day/Year) /2014		•	-	X Officer (give below) Chief I	e title Ot below) Executive Off	
(Street) NOVATO, CA 94949			4. If Amendment, Date Original Filed(Month/Day/Year)				6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting Person		
(City)	(City) (State) (Zip) Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned					ally Owned			
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code (Instr. 8)	4. Securit or Dispos (Instr. 3, 4	ed of (5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	01/06/2014(1)	01/06/2014	M	10,000	A	\$ 12.99	60,740	I	Shares Held in Bienaime Family Trust (2)
Common Stock	01/06/2014(1)	01/06/2014	S	5,000	D	\$ 67.4028 (<u>3)</u>	55,740	I	Shares held by Bienaime Family Trust (2)
	01/06/2014(1)	01/06/2014	S	5,000	D		50,740	I	

Edgar Filing: BIOMARIN PHARMACEUTICAL INC - Form 4

Common Stock	\$ 67.4164 (4)		Shares held by Bienaime Family Trust (2)
Common Stock	10,000	I	Held in irrevocable trust for Guillaume Bienaime (5)
Common Stock	10,000	I	Held in irrevocable trust for Pierre Bienaime (5)
Common Stock	10,000	I	Held in irrevocable trust for Paul Bienaime
Common Stock	10,000	I	Held in irrevocable trust for Marc Bienaime
Common Stock	20,000	I	Held in irrevocable trust for Aurelie Mitsuki Bienaime and Anais Kimiko (5)
Reminder: Report on a separate line for each class of securities benefic	cially owned directly or indirectly. Persons who respond to the collection	ction of	SEC 1474
	information contained in the Collect		SEC 1474

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

number.

information contained in this form are not

required to respond unless the form displays a currently valid OMB control

(9-02)

Edgar Filing: BIOMARIN PHARMACEUTICAL INC - Form 4

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactic Code (Instr. 8)	5. Number of orDerivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisab Expiration Date (Month/Day/Year		7. Title and Underlying (Instr. 3 and	Securitie
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amour or Numbe of Shar
Stock Option (right to buy Common Stock)	\$ 12.99	01/06/2014(1)	01/06/2014	M	10,000	11/11/2006 <u>(6)</u>	05/10/2016	Common Stock	10,00

Reporting Owners

Reporting Owner Name / Address	Relationships Director 10% Owner Officer			Other
BIENAIME JEAN JACQUES C/O BIOMARIN PHARMACEUTICAL INC. 105 DIGITAL DRIVE NOVATO, CA 94949	X		Chief Executive Officer	
Signatures				

/s/ Laura Randall Woodhead, 01/08/2014 Attorney-in-Fact

> **Signature of Reporting Person Date

Explanation of Responses:

- If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Transaction made pursuant to a Rule 10b5-1 trading plan executed on February 26, 2013.
- (2) The reporting person and his spouse act as trustees for the Bienaime Family Trust.
- The price in column 4 is a weighted average price. The price actually received ranged from \$66.77 to \$69.04. The reporting person will (3) provide to the issuer, any security holder of the issuer, ot th SEC staff, upon request, information regarding the number of shares sold at rach price within the range.
- The price in column 4 is a weighted average price. The price actually received ranged from \$66.77 to \$69.05. The reporting person will (4) provide to the issuer, any security holder of the issuer, ot th SEC staff, upon request, information regarding the number of shares sold at rach price within the range.
- (5) The reporting person's spouse is trustee of each child's trust.
- (6) Original option grant vests 6/48th on November 11, 2006, and 1/48th on the 11th day of every month thereafter
- (7) Reflects the number of stock options outstanding after the transaction from this specific stock option grant.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Reporting Owners 3

Edgar Filing: BIOMARIN PHARMACEUTICAL INC - Form 4

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.